SCHEMBL1862565

SCHEMBL1862565

C=CC(=O)Nc1c(C)cccc1OCOCC

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FGFR4 P22455 9/20 0.41
▸ EPHB4 P54760 2/20 0.41
▸ NLRP3 Q96P20 2/20 0.40
▸ FGFR1 P11362 4/20 0.39
▸ CYP3A4 P08684 2/20 0.39
▸ CYP2D6 P10635 1/20 0.39
▸ CYP2C9 P11712 1/20 0.39
▸ CYP2C19 P33261 1/20 0.39
▸ GSTO1 P78417 3/20 0.39
▸ KDR P35968 1/20 0.38
▸ TEK Q02763 1/20 0.38
▸ TGM2 P21980 1/20 0.37
▸ MAP2K7 O14733 1/20 0.36
▸ ALDH1A1 P00352 1/20 0.36
▸ LMNA P02545 1/20 0.36
▸ MAPT P10636 1/20 0.36
▸ MAPK1 P28482 1/20 0.36
▸ MC4R P32245 1/20 0.36
▸ SCN4A P35499 1/20 0.36
▸ MC3R P41968 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL409556 0.80 LMNA (0.54) CYP2C19ALDH1A1LMNAMAPT
SCHEMBL10027974 0.79 KMT2A (0.52) NLRP3ALDH1A1MAPK1
SCHEMBL9493239 0.77 EPHB4 (0.53) EPHB4CYP3A4CYP2C9CYP2C19KDR
SCHEMBL1867906 0.74 CYP1A2 (0.43) FGFR4FGFR1CYP2C9CYP2C19TGM2
SCHEMBL1864641 0.74 SMN1; SMN2 (0.46) FGFR4FGFR1CYP2C9CYP2C19TGM2
SCHEMBL1858964 0.73 HPGD (0.46) ALDH1A1LMNAMAPT
SCHEMBL13534910 0.71 MAOA (0.51) FGFR4EPHB4CYP2C9CYP2C19GSTO1
SCHEMBL11508899 0.71 FGFR4 (0.50) FGFR4EPHB4FGFR1CYP3A4CYP2D6
SCHEMBL25249826 0.70 ALDH1A1 (0.50) FGFR4EPHB4NLRP3FGFR1CYP3A4
SCHEMBL27771050 0.69 HTR1B (0.51) ALDH1A1LMNAMAPTMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7939241-B2 (Meth)acrylamide derivative, polymer, chemically amplified photosensitive resin composition, and patterning method NEC CORPORATION (JP) 2011-05-10 — — US disclosed
US-7939241-B2 (Meth)acrylamide derivative, polymer, chemically amplified photosensitive resin composition, and patterning method NEC CORPORATION (JP) 2011-05-10 — — US disclosed
US-20090068587-A1 (Meth) acrylamide derivative, polymer, chemically amplified photosensitive resin composition, and patterning method NEC CORPORATION (JP) 2009-03-12 — — US disclosed
US-20090068587-A1 (Meth) acrylamide derivative, polymer, chemically amplified photosensitive resin composition, and patterning method NEC CORPORATION (JP) 2009-03-12 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090068587-A1 (Meth) acrylamide derivative, polymer, chemically amplified photosensitive resin composition, and patterning method MMAB, DNMT3A, MAT1A FGFR4 3522/4885EPHB4 2794/4885NLRP3 1432/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback